Published in Cancer Epidemiol Biomarkers Prev on March 03, 2010
Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut (2010) 4.01
Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res (2012) 3.07
Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res (2011) 2.40
Interdisciplinary education to integrate pathology and epidemiology: towards molecular and population-level health science. Am J Epidemiol (2012) 2.07
Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. Mod Pathol (2013) 1.95
Risk factors for colorectal cancer in patients with multiple serrated polyps: a cross-sectional case series from genetics clinics. PLoS One (2010) 1.36
Genetic and epigenetic events generate multiple pathways in colorectal cancer progression. Patholog Res Int (2012) 1.24
Etiologic field effect: reappraisal of the field effect concept in cancer predisposition and progression. Mod Pathol (2014) 1.16
A prospective study of duration of smoking cessation and colorectal cancer risk by epigenetics-related tumor classification. Am J Epidemiol (2013) 1.08
Gene expression differences between colon and rectum tumors. Clin Cancer Res (2011) 1.03
Statistical methods for studying disease subtype heterogeneity. Stat Med (2015) 1.01
Progress and opportunities in molecular pathological epidemiology of colorectal premalignant lesions. Am J Gastroenterol (2014) 0.98
Lifestyle factors and their combined impact on the risk of colorectal polyps. Am J Epidemiol (2012) 0.97
BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis. PLoS One (2014) 0.97
Physical activity, tumor PTGS2 expression, and survival in patients with colorectal cancer. Cancer Epidemiol Biomarkers Prev (2013) 0.96
MLH1 promoter hypermethylation in the analytical algorithm of Lynch syndrome: a cost-effectiveness study. Eur J Hum Genet (2012) 0.94
No evidence for interference of h&e staining in DNA testing: usefulness of DNA extraction from H&E-stained archival tissue sections. Am J Clin Pathol (2012) 0.93
Colorectal cancers from distinct ancestral populations show variations in BRAF mutation frequency. PLoS One (2013) 0.88
Exome sequencing identifies MXRA5 as a novel cancer gene frequently mutated in non-small cell lung carcinoma from Chinese patients. Carcinogenesis (2012) 0.88
A Meta-Regression Method for Studying Etiological Heterogeneity Across Disease Subtypes Classified by Multiple Biomarkers. Am J Epidemiol (2015) 0.85
Clearing the air on smoking and colorectal cancer. J Natl Cancer Inst (2010) 0.82
Differential Effect of Active Smoking on Gene Expression in Male and Female Smokers. J Carcinog Mutagen (2015) 0.82
KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients. World J Gastroenterol (2015) 0.81
A very low incidence of BRAF mutations in Middle Eastern colorectal carcinoma. Mol Cancer (2014) 0.81
Television watching and risk of colorectal adenoma. Br J Cancer (2015) 0.79
Correlation between smoking history and molecular pathways in sporadic colorectal cancer: a meta-analysis. Int J Clin Exp Med (2015) 0.78
Putative effectors for prognosis in lung adenocarcinoma are ethnic and gender specific. Oncotarget (2015) 0.77
The role of EGFR monoclonal antibodies (MoABs) cetuximab/panitumab, and BRAF inhibitors in BRAF mutated colorectal cancer. J Gastrointest Oncol (2013) 0.76
MYOD1 (L122R) mutations are associated with spindle cell and sclerosing rhabdomyosarcomas with aggressive clinical outcomes. Mod Pathol (2016) 0.75
A Prospective Study of Smoking and Risk of Synchronous Colorectal Cancers. Am J Gastroenterol (2017) 0.75
Molecular Biomarkers of Colorectal Cancer and Cancer Disparities: Current Status and Perspective. Curr Colorectal Cancer Rep (2016) 0.75
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet (2006) 13.63
Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet (1994) 8.34
Statins and the risk of colorectal cancer. N Engl J Med (2005) 6.86
Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology (2005) 6.34
CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut (2008) 6.26
Eating patterns and risk of colon cancer. Am J Epidemiol (1998) 6.08
Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn (2005) 6.00
Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res (2005) 5.68
Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res (2008) 3.70
Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proc Natl Acad Sci U S A (2000) 3.65
Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol Biomarkers Prev (2001) 3.43
Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. J Natl Cancer Inst (2006) 3.08
Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology (2000) 3.01
Postmenopausal hormone use and risk of large-bowel cancer. J Natl Cancer Inst (1995) 2.24
Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis. Int J Cancer (2010) 2.08
Phenotype of microsatellite unstable colorectal carcinomas: Well-differentiated and focally mucinous tumors and the absence of dirty necrosis correlate with microsatellite instability. Am J Surg Pathol (2003) 1.97
Microsatellite instability: impact on cancer progression in proximal and distal colorectal cancers. Eur J Cancer (1999) 1.82
DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet (2002) 1.68
Estrogens reduce and withdrawal of estrogens increase risk of microsatellite instability-positive colon cancer. Cancer Res (2001) 1.67
BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. Oncogene (2005) 1.62
Estrogen plus progestin use, microsatellite instability, and the risk of colorectal cancer in women. Cancer Res (2007) 1.61
Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation. Pathol Int (2008) 1.52
Ethnicity and risk for colorectal cancers showing somatic BRAF V600E mutation or CpG island methylator phenotype. Cancer Epidemiol Biomarkers Prev (2008) 1.36
Risk of microsatellite-unstable colorectal cancer is associated jointly with smoking and nonsteroidal anti-inflammatory drug use. Cancer Res (2006) 1.31
Mismatch repair polymorphisms and risk of colon cancer, tumour microsatellite instability and interactions with lifestyle factors. Gut (2008) 1.26
Pathologic predictors of microsatellite instability in colorectal cancer. Am J Surg Pathol (2009) 1.23
Activated BRAF targets proximal colon tumors with mismatch repair deficiency and MLH1 inactivation. Genes Chromosomes Cancer (2004) 1.18
Evidence for an age-related influence of microsatellite instability on colorectal cancer survival. Int J Cancer (2002) 1.03
Interactions of familial and hormonal risk factors for large bowel cancer in women. Int J Epidemiol (1999) 1.02
Dietary sugar and colon cancer. Cancer Epidemiol Biomarkers Prev (1997) 0.95
Ethnic differences in colorectal cancer among Arab and Jewish neighbors in Israel. Am J Gastroenterol (2001) 0.95
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology (2003) 16.40
Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med (2002) 10.80
Statins and the risk of colorectal cancer. N Engl J Med (2005) 6.86
Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nat Genet (2008) 6.75
Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med (2011) 5.82
Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst (2006) 5.42
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med (2010) 4.81
Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat Genet (2007) 4.69
Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA (2006) 4.34
Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res (2003) 4.30
Statins and cancer prevention. Nat Rev Cancer (2005) 4.12
Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet (2002) 3.96
Retracted A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nat Genet (2009) 3.88
Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res (2006) 3.81
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet (2007) 3.63
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet (2008) 3.41
Small changes in expression affect predisposition to tumorigenesis. Nat Genet (2001) 3.37
Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol (2010) 3.30
Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2002) 3.25
Replication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: a pooled analysis from the International Lung Cancer Consortium. J Natl Cancer Inst (2010) 3.18
Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood (2005) 3.12
Mouse model of colonic adenoma-carcinoma progression based on somatic Apc inactivation. Cancer Res (2007) 2.97
Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut (2013) 2.86
Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res (Phila) (2010) 2.86
Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst (2008) 2.78
The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. Cell (2012) 2.78
Identification of Lynch syndrome among patients with colorectal cancer. JAMA (2012) 2.77
Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology (2009) 2.75
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol (2013) 2.72
Hepatic fat fraction: MR imaging for quantitative measurement and display--early experience. Radiology (2005) 2.69
Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancer. Proc Natl Acad Sci U S A (2009) 2.63
Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat Cell Biol (2006) 2.58
Identification of Genetic Susceptibility Loci for Colorectal Tumors in a Genome-Wide Meta-analysis. Gastroenterology (2012) 2.57
Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer (2002) 2.51
Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw (2010) 2.45
Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol (2010) 2.43
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet (2013) 2.39
Pretreatment health behaviors predict survival among patients with head and neck squamous cell carcinoma. J Clin Oncol (2009) 2.38
Meta-analysis of new genome-wide association studies of colorectal cancer risk. Hum Genet (2011) 2.35
Risk of pancreatic cancer in families with Lynch syndrome. JAMA (2009) 2.32
Genetic variation in 8q24 associated with risk of colorectal cancer. Cancer Biol Ther (2007) 2.32
The yield of colonoscopy in patients with non-constipated irritable bowel syndrome: results from a prospective, controlled US trial. Am J Gastroenterol (2010) 2.30
Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood (2011) 2.24
A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews. Am J Hum Genet (2002) 2.24
Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res (2003) 2.18
A DNA methylation fingerprint of 1628 human samples. Genome Res (2011) 2.16
Chromosomal instability correlates with genome-wide DNA demethylation in human primary colorectal cancers. Cancer Res (2006) 2.15
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2009) 2.13
NCCN clinical practice guidelines in oncology. Colorectal cancer screening. J Natl Compr Canc Netw (2010) 2.13
Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst (2005) 2.10
Vitamin D status in primary hyperparathyroidism. Eur J Intern Med (2011) 2.05
Tests for gene-environment interaction from case-control data: a novel study of type I error, power and designs. Genet Epidemiol (2008) 2.04
One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol (2005) 2.04
BLM heterozygosity and the risk of colorectal cancer. Science (2002) 2.03
Clinical phenotype of families with longevity. J Am Geriatr Soc (2004) 2.03
Phenotype of microsatellite unstable colorectal carcinomas: Well-differentiated and focally mucinous tumors and the absence of dirty necrosis correlate with microsatellite instability. Am J Surg Pathol (2003) 1.97
Comparison of seven methods for producing Affymetrix expression scores based on False Discovery Rates in disease profiling data. BMC Bioinformatics (2005) 1.96
Maximizing association statistics over genetic models. Genet Epidemiol (2008) 1.93
Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD. Am J Gastroenterol (2006) 1.91
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res (2010) 1.90
Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. PLoS Genet (2013) 1.88
The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. Genome Res (2009) 1.87
Cervical coinfection with human papillomavirus (HPV) types and possible implications for the prevention of cervical cancer by HPV vaccines. J Infect Dis (2005) 1.86
BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res (2006) 1.85
Use of bisphosphonates and reduced risk of colorectal cancer. J Clin Oncol (2011) 1.84
Low Paneth cell numbers at onset of gastrointestinal graft-versus-host disease identify patients at high risk for nonrelapse mortality. Blood (2013) 1.82
Population-based study of natural variation in the melanocortin-1 receptor gene and melanoma. Cancer Res (2006) 1.80
A design for cancer case-control studies using only incident cases: experience with the GEM study of melanoma. Int J Epidemiol (2006) 1.80
Accurate classification of MLH1/MSH2 missense variants with multivariate analysis of protein polymorphisms-mismatch repair (MAPP-MMR). Hum Mutat (2008) 1.76
BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer. J Natl Cancer Inst (2004) 1.76
K-ras codon-specific mutations produce distinctive metabolic phenotypes in NIH3T3 mice [corrected] fibroblasts. Cancer Res (2005) 1.73
Jumbo forceps are superior to standard large-capacity forceps in obtaining diagnostically adequate inflammatory bowel disease surveillance biopsy specimens. Gastrointest Endosc (2007) 1.72
Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin Gastroenterol Hepatol (2007) 1.71
The relationship between serum 25(OH)D and parathyroid hormone levels. Am J Med (2011) 1.70
Testing gene-environment interaction in large-scale case-control association studies: possible choices and comparisons. Am J Epidemiol (2011) 1.69
MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res (2011) 1.68